FCS
Fairchild Semiconductor Intl, Inc.
Set alert
19.86 0.00 0.00%
19.84 Day range 19.88
12.95 52-week range 21.71
- Open
- 19.88
- Prev close
- 19.86
- Mkt cap
- 0
- Vol
- 937.61K
- Avg vol
- 1.60M
- EPS
- 0.00
- P/E
- 0.00
More statistics
- Low
- 19.84
- High
- 19.88
- Earnings
- Oct 20, 2016
Next earnings
Oct 20, 2016
Expected Oct 20, 2016. Consensus EPS estimate 0.19.
Financials — quick view
FCS Revenue — quarterly 350.00M
FCS Net income — quarterly 6.90M
FCS EPS — quarterly 0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 20, 2016 | Sep 1, 2016 | 0.19 | — | — | — |
| Aug 8, 2016 | Jun 1, 2016 | 0.16 | — | — | — |
| Apr 21, 2016 | Mar 1, 2016 | 0.13 | — | — | — |
| Jan 28, 2016 | Dec 1, 2015 | 0.14 | — | — | — |
| Oct 15, 2015 | Sep 1, 2015 | 0.20 | — | — | — |
| Jul 16, 2015 | Jun 1, 2015 | 0.19 | — | — | — |
News
- Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
- NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales
- Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
- People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
- Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
- TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
- Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
- Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
- Esquire Bank Earns Multiple Honors at 2026 FCS Portfolio Awards
Your note
Sign in to keep a note on FCS — it syncs with the Stock Master app.